Two Upstarts that Could Dislodge Gilead's Hold on the Hepatitis C Market

Gilead Sciences (NASDAQ:GILD) is about to find out if the FDA will approve its latest hepatitis C drug, and if it does, then that approval will solidify Gilead Sciences as the Goliath in the hepatitis C treatment market. Gilead Sciences will rack up billions of dollars in hepatitis C drug sales in the next year, but efforts underway at smaller competitors to shorten treatment duration could pose a threat to the biotech giant in a couple years. Will Achillion Pharmaceuticals' (NASDAQ:ACHN) and Regulus Therapeutics' (NASDAQ:RGLS) promising R&D programs dislodge Gilead Sciences' grappling hold on the indication?